Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

2024.02.19
Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

2024.02.18
Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.
Combining PD-1 Monoclonal Antibody and HDAC Inhibitor with Conventional P-Gemox Significantly Improves the Treatment Outcome for NK/T Cell Lymphoma

Combining PD-1 Monoclonal Antibody and HDAC Inhibitor with Conventional P-Gemox Significantly Improves the Treatment Outcome for NK/T Cell Lymphoma

2024.01.18
From June 17th to 23rd, 2023, the 17th International Conference on Malignant Lymphoma (ICML) was held grandly in Lugano, Switzerland. As the world's largest conference on malignant lymphoma, ICML has become an essential event in the field of lymphoma research and treatment over the past decades, aiming to present and discuss the latest basic, translational, and clinical research on lymphoma. NK/T cell lymphoma is a relatively rare hematological malignancy with no standardized treatment regimen. At this conference, Dr. Huiqiang Huang from the Cancer Center of Sun Yat-sen University,China,  gave an enlightening lecture on the treatment strategy for NK/T cell lymphoma. Oncology Frontier has specially interviewed Professor Huang and compiled the contents as follows:
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

2024.01.15
Dr. Iskandar Azwa Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies. At the APACC 2023 conference, Dr. Iskandar Azwa delivered an insightful presentation on "The Role of Nucleosides in Second-Line HIV Treatment." Our journal had the privilege to conduct an in-depth interview with Dr. Azwa regarding the choices for second and third-line treatment for HIV/AIDS patients.
Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

2024.01.15
Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.
Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

Youth Forum of APACC 2023  | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

2024.01.14
Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.
Professor Chen Yaokai: A Systematic Review and Meta-Analysis of Raltegravir Treatment for HIV-Positive Pregnant Women

Professor Chen Yaokai: A Systematic Review and Meta-Analysis of Raltegravir Treatment for HIV-Positive Pregnant Women

2023.12.08
HIV can be transmitted through bodily fluids such as blood, breast milk, semen, and vaginal secretions. Pregnant women who are infected with HIV should receive antiretroviral therapy (ART) as soon as possible to protect their own health and reduce the risk of transmitting HIV to their unborn child. At the recent 19th European AIDS Conference (EACS 2023), Professor Chen Yaokai and his team from the Chongqing Public Health Medical Treatment Center presented a report titled "The Effectiveness of Raltegravir in Virological Suppression of HIV-Positive Pregnant Women at Delivery: A Systematic Review and Meta-Analysis." The study analyzed the effectiveness of Raltegravir treatment for pregnant women with HIV, initiated at different stages of pregnancy, in achieving virological suppression at the time of delivery, and conducted subgroup analyses for treated and untreated pregnant women.

What to start with? A review of current guidelines (EACS, WHO, DHHS)

2023.12.08
Hello. My name is Cristiana Oprea. I'm an infectious disease and HIV clinician at Victor Babes Hospital for infectious and tropical diseases in Bucharest, and also an associate professor at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. I am part of the European AIDS Clinical Society governing board since 2014, and also part of the EuroSida steering committee since 2017.